Compare Omnicom Group Inc. (OMC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Omnicom Group Inc. trades at $76.35 (market cap $20.54B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.2× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays a 4.27% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OMC | VRTX | |
|---|---|---|
Market Cap | $20.54B | $128.16B |
Volume | 1,803,209 | 806,603 |
Sector | Media | Health |
52-Week High | $88.94 | $557.96 |
52-Week Low | $67.27 | $407.37 |
Typical Hold Time | 63 Days | 120 Days |
Enterprise Value | $28.62B | $122.29B |
Dividend Yield | 4.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OMC trades at $76.45, up 1.8% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, though 2026 projections show a return to profitability. Recent news highlights leadership in digital marketing and significant new business wins, including $3.3 billion in H1 2026 billings.
The stock presents a value opportunity with a low P/S of 0.84 and a consensus price target of $104.67, implying 37% upside. However, high P/E of 202.35, recent net loss, and advertising market volatility pose risks. Analyst sentiment is cautious with 59% hold ratings, reflecting balanced near-term prospects.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
